GlassScriptPhysician profile
Tom L Meziere
NPI 1750385563
$5,188.59
in general payments reported to CMS, 2019-2025
25 companies · $30.21 in 2025
The $30.21 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $267 · 2021: $1,267 · 2022: $1,012 · 2023: $1,191 · 2024: $831 · 2025: $30.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017 · Education: $34.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.55 |
| Education | $34.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,389.43 | 2019-2025 | |
| Janssen Biotech, INC. | $652.33 | 2020-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $336.38 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $313.77 | 2019-2022 | |
| Celgene Corporation | $183.15 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $158.81 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.58 | 2019-2024 | Xifaxan, Plenvu |
| Ferring Pharmaceuticals INC. | $132.93 | 2019-2023 | Rebyota |
| Genzyme Corporation | $125.92 | 2023 | |
| Redhill Biopharma INC. | $113.97 | 2021 | |
| Merck Sharp & Dohme LLC | $108.96 | 2022-2024 | Dificid |
| Organon LLC | $97.05 | 2021-2023 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $67.22 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $57.87 | 2023 | Dupixent |
| Lilly USA, LLC | $52.10 | 2023-2024 | Omvoh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $48.08 | 2021-2023 | Gimoti |
| Amgen INC. | $47.88 | 2021 | |
| Qol Medical, LLC | $37.38 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $27.84 | 2021 | |
| Ironwood Pharmaceuticals, INC | $27.79 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $20.91 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.57 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $13.53 | 2025 | |
| Braintree Laboratories, INC. | $11.79 | 2020 | |
| Echosens North America, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Meziere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.